• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Recombinant interleukin-2 significantly increases the survival of mice with peritonitis, but not acute Staphylococcus aureus peritoneal infection.

作者信息

Shadrin O V, Kaufman O Y, Dronova O M, Bykovskaya S N

机构信息

Department of Cellular Immunology, All-Union Cancer Research Center, Moscow, Russia.

出版信息

Mol Biother. 1992 Sep;4(3):151-4.

PMID:1445671
Abstract

The effect of recombinant interleukin 2 (rIL-2) on survival of mice with peritonitis and acute Staphylococcus aureus strain 5/2 infection was studied. rIL-2 was ineffective in the case of acute infection when administered simultaneously with LD95 dose of bacteria. The antibiotics (gentamycin or a combination of penicillin and streptomycin) administered in the same fashion cured 100% of animals. rIL-2 proved to be a potent healing agent in the two of three models of S aureus peritonitis. In this case animals received bacteria at days 0 and 2, 4, or 6. rIL-2 was injected at day 0 (group 1), days 0 and 2 (group 2), and days 0, 2, and 4 (group 3). Treatment with rIL-2 was ineffective in group 1; however, in groups 2 and 3 rIL-2 increased the survival up to 90% (in comparison with 30% in the untreated animals of group 2 and 64% in group 3). On the contrary, administration of antibiotics instead of rIL-2 in the group 3 decreased survival to 25%. The perspectives of rIL-2 use in the treatment of bacterial peritonitis, including purous ones, and the cases complicated by immunodepression, are discussed.

摘要

相似文献

1
Recombinant interleukin-2 significantly increases the survival of mice with peritonitis, but not acute Staphylococcus aureus peritoneal infection.
Mol Biother. 1992 Sep;4(3):151-4.
2
[The effect of recombinant interleukin-2 on the course of experimental staphylococcal peritonitis in mice].[重组白细胞介素-2对小鼠实验性葡萄球菌性腹膜炎病程的影响]
Biull Eksp Biol Med. 1992 Oct;114(10):385-7.
3
[The prophylactic administration of interleukin-2 increases the survival of mice with an acute intra-abdominal infection caused by Staphylococcus aureus].[白细胞介素-2的预防性给药可提高由金黄色葡萄球菌引起的急性腹腔感染小鼠的存活率]
Biull Eksp Biol Med. 1992 Oct;114(10):383-5.
4
The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration.局部区域低剂量重组白细胞介素-2疗法在荷瘤小鼠中的成功取决于重组白细胞介素-2的给药时间。
J Exp Ther Oncol. 1996 Jul;1(4):231-6.
5
[The effect of intraperitoneal administration of OK-432 with recombinant interleukin-2 to patients with peritonitis carcinomatosa of recurrent gynecological cancer and changes in ascitic lymphocyte subsets].[腹腔注射OK-432联合重组白细胞介素-2对复发性妇科癌症腹膜癌患者的影响及腹水淋巴细胞亚群的变化]
Nihon Sanka Fujinka Gakkai Zasshi. 1991 May;43(5):489-96.
6
Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).局部照射联合瘤周注射低剂量重组白细胞介素-2(rIL-2)的抗肿瘤作用
Radiat Oncol Investig. 1997;5(2):54-61. doi: 10.1002/(SICI)1520-6823(1997)5:2<54::AID-ROI3>3.0.CO;2-I.
7
[The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].[人重组白细胞介素-2(rIL-2)在体内的抗肿瘤疗效]
Zhonghua Zhong Liu Za Zhi. 1995 Jan;17(1):27-9.
8
Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.用重组白细胞介素-2和环磷酰胺对小鼠黑色素瘤和肉瘤进行成功的免疫治疗。
J Biol Response Mod. 1986 Oct;5(5):411-22.
9
Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.用重组白细胞介素2和一种能够诱导抗体依赖性细胞毒性的抗肿瘤单克隆抗体对携带抗淋巴因子激活的杀伤细胞肿瘤的小鼠进行联合治疗。
Cancer Res. 1988 Mar 1;48(5):1173-9.
10
[Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].[使用人重组白细胞介素2和淋巴因子激活的杀伤细胞进行癌症治疗的策略]
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1290-7.